10th May 2005 07:00
Bespak PLC10 May 2005 10 May 2005 Bespak plc Trading update for the 52 weeks ended 30 April 2005 Bespak plc (LSE: BPK), a leader in specialty medical devices, today announcesthat trading for the year is consistent with its expectations, with activity inthe second half weighted to the final months of the period. The transfer ofcertain production from the Company's plant in Cary, North Carolina to the UKproceeds as planned towards an anticipated shut-down in August 2005. Looking ahead, two key issues will continue to influence our performance. InMarch, the FDA announced that CFC albuterol formulations cannot be sold in theUS after December 2008, and US customers are now considering the impact of thisruling. In February, Pfizer announced that it had filed the NDA for Exubera(R)in the US, which followed the European filing in February 2004. We remainconfident in our continuing growth prospects, although we are cautious in thenear term in view of a stepped increase in pension costs. Bespak will announce its full year results on 13 July 2005. For further information please call: Bespak plcMark Throdahl - Chief Executive +44 (0) 1908 552 600Martin Hopcroft - Group Finance Director Buchanan Communications +44 (0) 20 7466 5000Tim Thompson / Mark Court About Bespak plc Bespak, a specialty medical devices company, is at the forefront of developingnew delivery systems for the pharmaceutical industry. The company has a productrange covering metered dose inhalers, dry powder devices, actuators andcompliance aids. The company also develops and manufactures drug deliverydevices for leading global pharmaceutical companies. The group, which hasfacilities in King's Lynn and Milton Keynes in the UK and in Cary, NorthCarolina, in the USA. is a public company quoted on the Official list of theLondon Stock Exchange (LSE: BPK). For more information, please visitwww.bespak.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CSRT.L